Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy
Kitt Falk Petersen1, Elif Arioglu Oral, Sylvie Dufour
1Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520-8020, USA. kitt.petersen@yale.edu
Abstract:
Lipodystrophy is a rare disorder that is characterized by selective loss of subcutaneous and visceral fat and is associated with hypertriglyceridemia, hepatomegaly, and disordered glucose metabolism. It has recently been shown that chronic leptin treatment ameliorates these abnormalities. Here we show that chronic leptin treatment improves insulin-stimulated hepatic and peripheral glucose metabolism in severely insulin-resistant lipodystrophic patients. This improvement in insulin action was associated with a marked reduction in hepatic and muscle triglyceride content. These data suggest that leptin may represent an important new therapy to reverse the severe hepatic and muscle insulin resistance and associated hepatic steatosis in patients with lipodystrophy.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Dipeptidyl Peptidase 4 Inhibitors
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Insulin: The Receptor and Signaling Pathways
Oral Hypoglycemic Agents: Glinides


